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A B S T R A C T
Purpose
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated,
human epidermal growth factor receptor 2–positive metastatic breast cancer (MBC). We tested
the combination in the earlier-line setting and explored the predictive value of [18F]fluorodeoxyg-
lucose positron emission tomography ([18F]FDG-PET) for clinical outcomes.
Patients and Methods
Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and  1 year from adjuvant
trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC
and/or recurrence  1 year from adjuvant trastuzumab). The primary end point was objective
response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete
response plus partial response plus stable disease  24 weeks) and progression-free survival.
[18F]FDG-PET scans were acquired at baseline, week 1, and week 8. Associations between
metabolic response and clinical outcomes were explored.
Results
Eighty-seven patients were registered (85 were evaluable for efficacy). The confirmed objective
response rate was 50.0% (95% CI, 33.8% to 66.2%) in cohort 1 and 22.2% (95% CI, 11.3% to 37.3%)
in cohort 2. Clinical benefit rate was 57.5% (95% CI, 40.9% to 73.0%) in cohort 1 and 40.0% (95% CI,
25.7% to 55.7%) in cohort 2. Median progression-free survival was 7.4 and 5.3 months, respectively.
Lack of week-1 [18F]FDG-PET/computed tomography ([18F]FDG-PET/CT) response was associated
with failure to achieve an objective response by RECIST (negative predictive value, 91% [95% CI, 74%
to 100%] for cohort 1 and 91% [95% CI, 79% to 100%] for cohort 2).
Conclusion
Early use of lapatinib and trastuzumab is active in human epidermal growth factor receptor
2–positive MBC. Week-1 [18F]FDG-PET/CT may allow selection of patients who can be treated
with targeted regimens and spared the toxicity of chemotherapy.
J Clin Oncol 33:2623-2631. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2/
neu) plays a central role in tumorigenesis.1,2 In the
first-line setting, trastuzumab monotherapy pro-
duces objective responses in approximately one
third of patients with HER2-positive metastatic
breast cancer (MBC); response rates are higher
when trastuzumab is combined with chemother-
apy.3,4 Preclinical models suggest synergy between
trastuzumab and the HER2-directed tyrosine kinase
inhibitor lapatinib.5 At the time this study was con-
ceived, phase I data were available for the doublet.6
Since then, a phase III study comparing lapatinib
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with lapatinib plus trastuzumab demonstrated improvements in
progression-free survival (PFS) and overall survival (OS) with the
combination in heavily pretreated patients who had received a median
of three prior trastuzumab-based regimens.7,8
The cost of [18F]fluorodeoxyglucose positron emission tomog-
raphy/computed tomography ([18F]FDG-PET/CT) is covered by the
Centers for Medicare & Medicaid Services and third-party insurers for
monitoring response to treatment in patients with distant metastasis.
However, because of the lack of prospective data regarding the utility
of [18F]FDG-PET/CT over CT alone in MBC, the 2014 National
Comprehensive Cancer Network guidelines “generally discourage”
[18F]FDG-PET/CT “except in those situations in which other staging
studies are equivocal or suspicious.”9 An advantage of [18F]FDG-
PET/CT over anatomic imaging such as CT is its ability to detect
changes in tumor metabolism, often before changes in tumor size, and
provide an early indicator of efficacy. Although this paradigm is widely
used in some disease settings (eg, lymphoma), prospective data in
MBC are lacking. Given that glucose uptake is regulated by the PI3K/
AKT pathway, which itself is strongly activated by HER2, we hypoth-
esized that effective HER2 inhibition should result in a reduction in
[18F]FDG uptake in responsive tumors.10
We evaluated the combination of trastuzumab and lapatinib in
patients with HER2-positive MBC earlier in their course of disease
(zero to two prior lines of therapy). As a secondary end point, we
evaluated the predictive value of early metabolic imaging with respect
to traditional clinical outcomes.
PATIENTS AND METHODS
Patients
The study enrolled patients with MBC who met the following key crite-
ria: histologically or cytologically confirmed invasive breast cancer, age  18
years, Eastern Cooperative Oncology Group performance status 0 to 2, at least
one measurable lesion by RECIST (Response Evaluation Criteria in Solid
Tumors) v1.0, and primary and/or metastatic tumor with HER2 overexpres-
sion (3by immunohistochemistry) or gene amplification (fluorescent in situ
hybridization ratio  2.0). Adequate organ function, including left ventricular
ejection fraction (LVEF)  50%, was required. Prior lapatinib was prohibited.
Prior trastuzumab, pertuzumab, and/or trastuzumab emtansine were allowed.
Patients with active brain metastases were excluded; stable brain metastases
were allowed. A washout period of 2 weeks from chemotherapy was required.
Study Design
This was a nonrandomized phase II study. Cohort 1 included patients
without prior trastuzumab for MBC. Adjuvant or neoadjuvant trastuzumab
was allowed, if the interval from trastuzumab completion to recurrence ex-
ceeded 1 year. Cohort 2 included patients with one to two lines of chemother-
apy for metastatic disease with at least one trastuzumab-containing regimen or
patients who recurred within 12 months of adjuvant or neoadjuvant trastu-
zumab with up to one line of metastatic trastuzumab-based therapy. A base-
line research biopsy for correlative studies was required; results of these
analyses will be reported separately. Initially, patients received lapatinib 1,000
mg orally once per day and intravenous trastuzumab 2 mg/kg (following a
4-mg/kg loading dose) once per week. In July 2009, the study was amended to
allow trastuzumab 6 mg/kg (after an 8-mg/kg loading dose) once every 3
weeks. Lapatinib dose modifications were per protocol according to a pre-
defined algorithm. Adverse events (AEs) were assessed according to the Na-
tional Cancer Institute Common Terminology Criteria for Adverse Events
version 3.0. Cardiac evaluations (echocardiogram or multiple gated acquisi-
tion scans) were obtained every 8 weeks and then every 16 weeks if a patient
had three consecutive normal assessments. Tumor assessments were per-
formed every 8 weeks, but they decreased to every 12 weeks for patients who
had been on study for 12 or more cycles. Magnetic resonance imaging scans of
the brain at baseline and every 8 weeks were required for patients with a history
of brain metastases. The institutional review board for each participating
institution approved the study protocol. All patients provided written in-
formed consent.
Assessment of [18F]FDG-PET/CT Scans
Whole-body [18F]FDG-PET/CT scans were obtained at baseline, after 1
week, and after 8 weeks of treatment, in accordance with National Cancer
Institute guidelines for [18F]FDG-PET/CT as an indicator of therapeutic re-
sponse.11 Scanner qualification, central quality assurance, and image analysis
were performed by investigators at Dana-Farber Cancer Institute who were
blinded to clinical outcome data. Up to five target lesions were assessed by
using European Organisation for Research and Treatment of Cancer criteria:
complete metabolic response, complete metabolic resolution of [18F]FDG
uptake in all lesions, partial metabolic response (PMR),  25% reduction in
maximum standardized uptake value (SUVmax), progressive metabolic dis-
ease, more than 25% increase in SUVmax and/or new [
18F]FDG-avid lesion(s),
or stable metabolic disease (SMD), if the patient did not meet criteria for either
metabolic response or progression.12
Study End Points
The primary study end point was objective response (complete response
[CR] plus partial response [PR]) by investigator assessment using RECIST
v1.0. Secondary end points included safety, PFS, site(s) of first progression,
clinical benefit rate (CR plus PR plus stable disease  24 weeks), and OS. The
association between metabolic response and RECIST response was a second-
ary correlative end point.
Statistical Analysis
The study used Simon’s two-stage minimax designs with a one-sided
 .05 and 80% power to detect the acceptable response rates. Sample size was
calculated to distinguish between a response rate of 25% versus 45% in cohort
1 and 10% versus 25% in cohort 2. The observed response rates were to be
reported with 95% CIs for the two-stage designs.13 Post hoc exploratory
analyses of objective response rate (ORR) and PFS by hormone receptor (HR)
status were performed. In the case of discordance in HR status between
primary tumor and metastasis, HR results from the metastatic sample were
used in the analysis.
AEs were tabulated by grade for all events and for events deemed
possibly, probably, or definitely attributed to protocol therapy. Estimation
for PFS and OS were calculated by using the Kaplan-Meier product-limit
method. All estimates for secondary end points were computed by using
single-stage 95% CIs.
For [18F]FDG-PET/CT analyses, the protocol prespecified plan was to
combine cohorts 1 and 2. Because of the differences in response rates and PFS,
we chose to analyze cohorts 1 and 2 separately; this decision was made before
analysis of the [18F]FDG-PET/CT data. Kappa statistics and McNemar’s test
were used to evaluate the agreement between week-1 and week-8 metabolic
response. The association between week-1 metabolic response and objective
response by RECIST v1.0 is summarized by positive predictive value and
negative predictive value with 95% CIs calculated by using Wald’s method.
Landmark analysis was used to evaluate PFS; only patients who had a
follow-up [18F]FDG-PET/CT and were progression-free at week 1 were in-
cluded in the analysis, and progression-free intervals were recalculated from
that start date.14 Statistical analyses were performed by using SAS 9.4 (SAS
Institute, Cary, NC) and R version 2.6.1.15
RESULTS
Patients and Treatment
Eighty-seven patients were registered between May 2007 and
October 2010. One patient canceled before start of protocol therapy
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2624 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
and is not included in the analyses. One patient was found not to have
MBC on review of her baseline biopsy after initiation of protocol
therapy and is included in the safety (n  86) but not the efficacy (n
 85) analyses. Retrospective review of patient medical records
later determined that some patients had received more than the
allowed number of prior regimens. All analyses are based on initial
cohort assignment per treating investigator. In both cohorts, the
number of responses in the first stages (10 of 17 in cohort 1 and six
of 22 in cohort 2) were sufficient to continue enrollment onto the
second stage.
Baseline characteristics are provided in Table 1. Cohort 1 in-
cluded a higher proportion of patients with de novo metastatic disease
than cohort 2 (39% v 20%) and fewer patients who had received
neoadjuvant trastuzumab (20% v 47%).
The median follow-up for all surviving patients was 37.1 months
(maximum, 72.8 months). The reasons for discontinuation of proto-
col therapy were progression in non-CNS only (n  68; 79%), isolated
CNS progression (n  5; 6%), progression in both non-CNS and CNS
(n  2; 2%), treatment-related toxicity (n  1; 1%), physician or
patient decision (n  5; 6%), or review of baseline biopsy indicating
the patient did not have MBC (n  1; 1%). At the time of data lock
(November 30, 2013), four patients were still receiving protocol ther-
apy, all in cohort 1, with duration exceeding 3 years. Of these patients,
one had received adjuvant trastuzumab for stage III breast cancer, and
the other three were trastuzumab-naive (see Appendix Table A1,
online only). Among 85 patients evaluable for efficacy, 49 deaths were
observed. Surviving patients were censored at the last time point that
vital status was known: 15 patients were known to be alive at database
lock, 14 patients completed 2 years of follow-up after discontinuing
therapy, five patients were lost to follow-up, and two patients with-
drew consent.








No. (%) No. (%) No. (%)
Median age, years (range) 52 (32-83) 55 (32-77) 50 (33-83)
Sex
Female 86 (100) 41 (100) 45 (100)
Male 0 (0) 0 (0) 0 (0)
Race
White 79 (92) 36 (88) 43 (96)
Black or African American 4 (5) 2 (5) 2 (4)
Asian 1 (1) 1 (2) 0 (0)
Other 2 (2) 2 (5) 0 (0)
Ethnicity
Hispanic or Latino 4 (5) 3 (7) 1 (2)
Non-Hispanic 78 (91) 35 (85) 43 (96)
Unknown 4 (5) 3 (7) 1 (2)
ECOG PS at baseline
0 56 (65) 26 (63) 30 (67)
1 28 (33) 14 (34) 14 (31)
2 2 (2) 1 (2) 1 (2)
Stage at initial diagnosis
I 9 (10) 4 (10) 5 (11)
II 22 (26) 11 (27) 11 (24)
III 28 (33) 10 (24) 18 (40)
IV 25 (29) 16 (39) 9 (20)
Unknown 2 (2) 0 (0) 2 (4)
Hormone receptor status
Primary tumor
ER positive and/or PgR positive 52 (60) 27 (66) 25 (56)
ER negative and PgR negative 32 (37) 13 (32) 19 (42)
Unknown/not done 2 (2) 1 (2) 1 (2)
Metastatic lesion
ER positive and/or PgR positive 41 (48) 16 (39) 25 (56)
ER negative and PgR negative 33 (38) 17 (41) 16 (36)
Unknown/not done 12 (14) 8 (20) 4 (9)
HER2 status
Primary tumor
Positive 70 (81) 33 (80) 37 (82)
Negative/equivocal 10 (12) 5 (12) 5 (11)
Unknown/not done 6 (7) 3 (7) 3 (7)
Metastatic lesion
Positive 73 (85) 33 (80) 40 (89)
Negative/equivocal 1 (1) 0 (0) 1 (2)
Unknown/not done 12 (14) 8 (20) 4 (9)
Disease-free interval, years
0 (de novo metastatic breast
cancer) 25 (29) 16 (39) 9 (20)
 2 22 (26) 8 (20) 14 (31)
 2 39 (45) 17 (41) 22 (49)
Median No. of metastatic disease
sites (range) 3 (1-6) 3 (1-6) 2 (1-5)
Disease site
CNS 6 (7) 1 (2) 5 (11)
Lung 32 (37) 20 (49) 12 (27)
Pleural effusion 7 (8) 3 (7) 4 (9)
Liver 38 (44) 20 (49) 18 (40)
Bone 39 (45) 19 (46) 20 (44)
Breast or chest wall 46 (53) 22 (54) 24 (53)
Lymph nodes 59 (69) 32 (78) 27 (60)
Other 11 (13) 6 (15) 5 (11)
Adjuvant or neoadjuvant hormonal
therapy 32 (37) 11 (27) 21 (47)
(continued in next column)








No. (%) No. (%) No. (%)
Adjuvant or neoadjuvant
chemotherapy 46 (53) 19 (46) 27 (60)
Anthracycline 42 (49) 17 (41) 25 (56)
Taxane 38 (44) 14 (34) 24 (53)
Trastuzumab 29 (34) 8 (20) 21 (47)
No. of lines of chemotherapy for
metastasis or recurrence
None 46 (53) 39 (95) 7 (16)
1 21 (24) 1 (2) 20 (44)
2 15 (17) 0 (0) 15 (33)
 3 4 (5) 1 (2) 3 (7)
Prior chemotherapy for metastasis
or recurrence
Trastuzumab 39 (45) 1 (2) 38 (84)
Trastuzumab-emtansine 1 (1) 1 (2) 0 (0)
Pertuzumab 0 (0) 0 (0) 0 (0)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; ER, estrogen receptor; HER2, human epidermal growth factor receptor
2; PgR, progesterone receptor.
Retrospective review of patient records later determined that some patients
had received more than the allowed number of prior regimens. All analyses
were based on initial cohort assignment per treating investigator.
Lapatinib and Trastuzumab in HER2-Positive MBC
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Efficacy
Confirmation of response  4 weeks later was required for a CR
or PR. As delineated in Table 2, the confirmed ORR was 50.0% (95%
CI, 33.8% to 66.2%) in cohort 1 and 22.2% (95% CI, 11.3% to 37.3%)
in cohort 2. Median PFS was 7.4 months (95% CI, 3.9 to 9.3 months)
in cohort 1 and 5.3 months (95% CI, 3.7 to 6.7 months) in cohort 2
(Fig 1). In cohort 1, median OS was not reached; survival rate at 3
years was 61.7% (95% CI, 46.9% to 81.2%). In cohort 2, median
OS was 31.6 months (95% CI, 25.9 to 39.8 months) with survival
rate at 3 years of 38.6% (95% CI, 26.2% to 56.9%). The clinical
benefit rate was 57.5% (95% CI, 40.9% to 73.0%) in cohort 1 and
40.0% (95% CI, 25.7% to 55.7%) in cohort 2 (Table 2). ORR and
PFS according to HR status are presented in Table 2. Because this
was a post hoc analysis, we chose not to formally compare out-
comes by HR status but instead to present the data descriptively.
Among patients with HR-negative tumors treated in the first-line
setting, ORR was 63.2% (95% CI, 38.4% to 83.7%). ORR was
38.1% (95% CI, 18.1% to 61.6%) among patients with HR-positive
tumors receiving first-line therapy.
Safety
The most common AEs were diarrhea, fatigue, and rash (Appen-
dix Table A2, online only). No grade 4 toxicities were reported. Grade
3 diarrhea was reported in less than 10% of patients. Four patients
(5%) experienced a decline in LVEF to below 50%, with a lowest value
of 45%. All four patients recovered their LVEF and continued proto-
col therapy. No grade 3 or 4 cardiac events were reported. Dose holds
and dose reductions were required in less than 10% of patients, most
commonly for diarrhea or rash.
[18F]FDG-PET/CT Metabolic Assessments
Week-1 PMR was observed in 28 (71.8%) of 39 patients in cohort
1 and 21 (48.8%) of 43 of patients in cohort 2 (Appendix Fig A1, online
only). Week-8 PMR was observed in 28 (82.5%) of 34 patients in
cohort 1 and 18 (42.9%) of 42 patients in cohort 2. Week-1 and week-8
metabolic responses showed substantial agreement (, 0.66) and no
shift in the rates of response was detected in the paired measures
(McNemar’s test P  .29; Appendix Table A3 and Appendix Table A4,
online only).
In cohort 1, 19 (67.9%) of 28 patients who achieved a week-1
metabolic response subsequently achieved a confirmed objective re-
sponse by RECIST v1.0 compared with one (9.1%) of 11 patients with
SMD or progressive metabolic disease at week 1 (Table 3; Fig 2, and
Appendix Fig A2, online only). In cohort 2, seven (33%) of 21 patients
who achieved a week-1 PMR went on to achieve a confirmed objective
response compared with two (9.1%) of 22 of patients with week-1
SMD. These data suggest a strong negative predictive value (NPV;
91% [95% CI, 74% to 100%] for cohort 1 and 91% [95% CI, 79% to
100%] for cohort 2) of week-1 metabolic response for objective re-
sponse, with positive predictive value varying by cohort (68% [95%
CI, 51% to 85%] in cohort 1 and 33% [95% CI, 13% to 53%] in cohort
2). Similar results were seen when evaluating week-1 metabolic re-
sponse for prediction of clinical benefit (Appendix Table A5, online
only) and when evaluating week-8 metabolic response (Appendix
Table A6, online only).
Landmark analyses were performed to describe the associations
between week-1 metabolic response and PFS (Fig 3). In cohort 1,
patients with week-1 PMR experienced a median interval of 8.8
months (95% CI, 5.3 to 29.1 months) until progression versus 1.6
months (95% CI, 1.4 months to infinity) in patients without a week-1
PMR. In cohort 2, patients with a week-1 PMR experienced a median
interval of 5.3 months (95% CI, 5.1 to 7.9 months) until progression,
whereas patients without a week-1 PMR experienced a median inter-
val of 3.2 months (95% CI, 1.6 to 5.3 months; Fig 3).
DISCUSSION
We evaluated trastuzumab plus lapatinib in patients with HER2-
positive MBC and observed a response rate of 50.0% (95% CI, 33.8%
to 66.2%) in the first-line and 22.2% (95% CI, 11.3% to 37.3%) in the
second- and third-line settings. Fifty-seven percent of patients in co-
hort 1 and 40.0% of patients in cohort 2 achieved clinical benefit. Our
data compare favorably with that for single-agent trastuzumab or
lapatinib, in which first-line response rates between 24% and 35%
have been reported.3,16 Furthermore, we demonstrated that lack of
metabolic response by [18F]FDG-PET/CT at week 1 was highly pre-
dictive of poor response by RECIST v1.0 (NPV, 91% [95% CI, 74% to
100%] for cohort 1 and 91% [95% CI, 79% to 100%] for cohort 2).
Notably, in cohort 1, lack of week-1 metabolic response was associated
with median PFS of only 1.6 months compared with 8.8 months in
patients with an early metabolic response.
Our study was initiated in 2007, but since then, the treatment
landscape for HER2-positive breast cancer has changed dramatically.
Data from the CLEOPATRA trial (A Study to Evaluate Pertuzumab 
Trastuzumab  Docetaxel vs. Placebo  Trastuzumab  Docetaxel
in Previously Untreated HER2-positive Metastatic Breast Cancer)
have demonstrated the value of first-line pertuzumab when added
to trastuzumab/taxane.17 In second-line therapy, trastuzumab
emtansine improves PFS and OS compared with lapatinib plus cape-
citabine.18 For patients newly diagnosed with HER2-positive MBC,
these regimens now represent standard options.19 In the adjuvant
setting, although there was optimism for the addition of lapatinib to
trastuzumab based on improvements in pathologic complete re-
sponse (pCR) in preoperative trials,20-24 as well as a high rate of pCR
and near-pCR with lapatinib and trastuzumab without chemother-
apy,25 the ALTTO (Adjuvant Lapatinib And/Or Trastuzumab
Treatment Optimisation) Study; BIG 2-06/N063D trial did not
demonstrate concomitant gains in disease-free survival or OS
when lapatinib was incorporated into trastuzumab-based adjuvant
therapy.26 Despite these disappointing results in patients with
early-stage disease, we believe the activity of lapatinib and trastu-
zumab in our study is notable, particularly given the favorable
toxicity profile, and remains relevant in the metastatic setting. Of
note, four (10%) of 40 patients in cohort 1 remained on protocol
therapy more than 3 years after study entry.
Because the number of treatment options and their cost for
patients with HER2-positive breast cancer continues to increase, a key
question is how best to tailor therapies to individual patients. In the
metastatic setting, predictive tests for clinical benefit could spare pa-
tients unnecessary toxicity and cost from ineffective therapies and
maximize the likelihood of meaningful improvements from treat-
ment. In the early-stage setting, predictive tests may reduce both
under- and overtreatment.
To date, minimal prospective data are available regarding testing
of the incremental utility of advanced imaging techniques such as
Lin et al
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[18F]FDG-PET/CT in MBC relative to conventional CT imaging.27 An
exception to this is a recent phase IB study of buparlisib in patients
with HR-positive/HER2-negative tumors.28 The study reported a re-
lationship between day 15 [18F]FDG-PET/CT and time on treatment;
however, only 17 patients were evaluable for metabolic response. To
the best of our knowledge, ours is the largest prospective study to date
reporting on correlations between early metabolic response and clin-
ical outcomes in patients with uniformly treated HER2-positive
Table 3. Association Between Week-1 Metabolic Response and Objective Response by RECIST v1.0
Week-1 Metabolic Response Total
Objective Response Predictive Value
No. of Responders (%) No. of Nonresponders (%) PPV (%) 95% CI NPV (%) 95% CI
Cohort 1
PMR 28 19 (68) 9 (32) 68 51 to 85 91 74 to 100
SMD/PMD 11 1 (9) 10 (91)
Unknown 1 0 (0) 1 (100)
Total 40 20 (50) 20 (50)
Cohort 2
PMR 21 7 (33) 14 (67) 33 13 to 53 91 79 to 100
SMD 22 2 (9) 20 (91)
Unknown 2 1 (50) 1 (50)
Total 45 10 (22) 35 (78)
NOTE. Patients were tabulated by objective response (responder v nonresponder) and metabolic response (partial metabolic response [PMR] v stable metabolic
disease [SMD]/progressive metabolic disease [PMD]). Objective response was based on RECIST v1.0 (responder: confirmed complete response or partial response;
nonresponder: unconfirmed partial response, stable disease, progressive disease, or unknown). Metabolic response was based on European Organisation for
Research and Treatment of Cancer criteria.


























No. at risk 40 12 7 4 2
Median PFS, 7.4 months
(95% CI, 3.9 to 9.3)
Median PFS, 5.3 months
(95% CI, 3.7 to 6.7)
Median OS, not reached Median OS, 31.6 months
(95% CI, 25.9 to 39.8)
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No. at risk 45 41 30 14 5 3 2
0 2412 36 48 7260
Fig 1. Progression-free survival (PFS) for (A) cohort 1, no prior trastuzumab in the advanced setting (n  40), and (B) cohort 2, up to two lines of chemotherapy
including trastuzumab for metastatic breast cancer (n  45). Overall survival (OS) for (C) cohort 1 and (D) cohort 2. Shaded areas depict the 95% CIs.
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Fig 2. Relationship between change in maximum standardized uptake value (SUVmax) and objective response by RECIST v1.0. Paired [18F]fluorodeoxyglucose positron emission
tomography/computed tomography scan data were available for 82 patients at week 1 and for 76 patients at week 8. One patient’s best overall response was not evaluable and was
excluded from the figure. Dashed lines denote European Organisation for Research and Treatment of Cancer cutoffs for metabolic response (25%) and progression (25%). Color
codes indicate objective response for each patient according to RECIST v1.0. (A) Cohort 1 and (B) cohort 2 SUVmax at week 1 v baseline. (C) Cohort 1 and (D) cohort 2 SUVmax at



























































  No. of No. Censored
 No. of Events Within Within
 Patients 24 Months 24 Months
PMR 28 20 8
SMD/PMD 11 10 1
 No. of No. of No.
 Patients Events Censored
PMR 21 20 1
SMD/PMD 22 21 1
Fig 3. Association between week-1 metabolic response by [18F]fluorodeoxyglucose positron emission tomography (PET) /computed tomography and progression-
free survival (PFS). Patients were grouped according to those with a partial metabolic response (PMR) by European Organisation for Research and Treatment of Cancer
criteria, defined as  25% decrease in maximum standardized uptake value relative to baseline v those with either stable metabolic disease (SMD) or progressive
metabolic disease (PMD). PFS was calculated from the date of the landmark (week 1). (A) Cohort 1 patients with a week-1 PMR had a median PFS of 8.8 months (95%
CI, 5.3 to 29.1 months) and those without a week-1 PMR had a median PFS of 1.6 months (95% lower CI, 1.4 months). (B) Cohort 2 patients with a week-1 PMR had
a median PFS of 5.3 months (95% CI, 5.1 to 7.9 months) and those without a week-1 PMR had a median PFS of 3.2 months (95% CI, 1.6 to 5.3 months).
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advanced breast cancer. We believe the high NPV is of interest and, if
confirmed, it may allow clinicians to use a widely available imaging
modality to discontinue ineffective therapies. Consistent with the role
of HER2/PI3K/AKT in glucose uptake, the absence of a week-1 met-
abolic response in nonresponding patients suggests that the combina-
tion of lapatinib and trastuzumab was unable to inhibit HER2
function in these cancers. Future trials might consider evaluating
targeted combinations with an early “metabolic look” to determine
whether the addition of cytotoxic agents and/or an early treatment
switch is indicated. We acknowledge that such trials will be expensive
to launch. We also acknowledge that switching therapies on the basis
of other early predictive tests, such as circulating tumor cell burden, as
assessed in the S0500 (Treatment Decision Making Based on Blood
Levels of Tumor Cells in Women With Metastatic Breast Cancer
Receiving Chemotherapy) trial, has not been shown to improve OS.29
However, we would argue that OS is not the only end point of impor-
tance to patients and that methods for identifying patients who can do
well with less toxic regimens will be increasingly important as the
number of treatment regimens for MBCs (with their attendant AEs)
continue to expand.
Our data are also consistent with evidence in the preoperative
setting linking early metabolic response with pCR.30,31 In the Neo
ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Op-
timisation) Study, the rate of pCR was higher among patients who
achieved a week-2 metabolic response compared with patients with-
out a week-2 metabolic response (n  68 with baseline and week-2
data; pCR, 42% v 21%; P  .12).31 Our study supports continued
exploration of this approach in preoperative and metastatic trials. The
Translational Breast Cancer Research Consortium is exploring the
value of preoperative [18F]FDG-PET/CT for pCR with an all-biologic
regimen of trastuzumab and pertuzumab (Translational Breast Can-
cer Research Consortium [TBCRC] 026; [NCT01937117]; Pertu-
zumab and Trastuzumab as Neoadjuvant Treatment in Patients With
HER2-Positive Breast Cancer); related initiatives by the Breast Inter-
national Group are under way to elucidate whether evaluation of early
metabolic response can reduce the need for cytotoxic chemotherapy
in lieu of targeted approaches.
Our study has several limitations. First, the treatment landscape
for HER2-positive breast cancer continues to evolve. Although we
believe that our data support lapatinib and trastuzumab as a valid
option in the metastatic setting, we recognize that other options, such
as pertuzumab-trastuzumab-taxane combinations may be preferred
in many circumstances.19 We acknowledge that the [18F]FDG-
PET/CT analyses are exploratory and will need to be confirmed before
early metabolic response can influence treatment recommendations
in routine clinical practice. In addition, novel methods for assessing
metabolic response, such as PET Response Criteria in Solid Tumors
(PERCIST), have been developed.32 In the future, we plan to explore
the performance of PERCIST and other metabolic parameters versus
European Organisation for Research and Treatment of Cancer criteria
in our data set. Finally, our results regarding the predictive value of
early metabolic response may or may not be generalizable to other
regimens, including chemotherapy and other targeted therapies.
In summary, the combination of lapatinib and trastuzumab is
active and well tolerated in patients with HER2-positive MBC who
have received up to two lines of therapy for advanced disease. Use of
early metabolic imaging as a clinically relevant biomarker merits ad-
ditional investigation, particularly in studies with molecularly targeted
therapies. Finally, several molecular correlative analyses of metastatic
specimens are under way in the context of this study to elucidate
mechanisms of HER2 resistance.
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GLOSSARY TERMS
HER2/neu (human epidermal growth factor recep-
tor 2): also called ErbB2. HER2/neu belongs to the epidermal
growth factor receptor (EGFR) family and is overexpressed in
several solid tumors. Like EGFR, it is a tyrosine kinase receptor
whose activation leads to proliferative signals within the cells. On
activation, the human epidermal growth factor family of recep-
tors are known to form homodimers and heterodimers, each
with a distinct signaling activity. Because HER2 is the preferred
dimerization partner when heterodimers are formed, it is impor-
tant for signaling through ligands specific for any members of the
family. It is typically overexpressed in several epithelial tumors.
negative predictive value: the probability of a negative test
result being truly negative.
pathologic complete response: the absence of any resid-
ual tumor cells in a histologic evaluation of a tumor specimen.
PI3K/AKT pathway: signal transduction pathways involving the
signaling molecules phosphatidylinositol-3 kinase (PI3K) and AKT,
where PI3K generates phosphorylated inositides at the cell membrane,
which are required for the recruitment and activation of AKT, a trans-
forming serine-threonine kinase involved in cell survival.
positive predictive value: the probability of a positive test result
being truly positive.
RECIST (Response Evaluation Criteria in Solid
Tumors): a model proposed by the Response Evaluation Criteria
Group by which a combined assessment of all existing lesions, charac-
terized by target lesions (to be measured) and nontarget lesions, is used
to extrapolate an overall response to treatment.
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034 IV ER positive/PgR positive ER negative/PgR negative None No No
042 II ER negative/PgR negative Not done/not done Anthracycline and taxane based No No
064 III ER positive/PgR positive Not done/not done Anthracycline based No No
087 III ER negative/PgR negative ER negative/PgR negative Anthracycline and taxane based Yes No
Abbreviations: ER, estrogen receptor; ID, identification; PgR, progesterone receptor.
Table A2. Summary of AEs With at Least 10% Incidence (all grades or any grade 3 or 4) Deemed Related (definite, probable, possible) to Protocol Therapy,
Cohorts 1 and 2 Combined
AE
Maximum Grade
Total 1 (mild) 2 (moderate) 3 (severe)
Diarrhea without prior colostomy 55 41 8 6
Fatigue 45 38 6 1
Acne/acneiform rash 35 21 14 0
Nausea 22 21 1 0
AST 21 17 4 0
Hyperglycemia 14 13 1 0
Anorexia 13 11 2 0
Vomiting 12 10 2 0
ALT 10 6 4 0
Nail changes 10 7 3 0
Headache 9 8 1 0
Hemoglobin 9 8 1 0
Mucositis/stomatitis by examination of oral cavity 9 7 2 0
Rash/desquamation 9 6 3 0
GI, other 1 0 0 1
Hypokalemia 1 0 0 1
NOTE. All patients who received at least one dose of protocol therapy were included in this analysis (n  86). No grade 4 toxicities were reported on study.
Abbreviation: AE, adverse event.
Table A3. No. of Patients With [18F]FDG-PET/CT Scan Data by Time Point and Cohort
Time Point Cohort 1 Cohort 2 Total
Baseline 39 44 83
Week 1 39 43 82
Week 8 34 42 76
Week 1 and week 8 34 41 75
NOTE. Eighty-seven patients were enrolled onto the trial (cohort 1, 41; cohort 2, 46). Per protocol, patients underwent [18F]fluorodeoxyglucose positron emission
tomography/computed tomography ([18F]FDG-PET/CT) scans at baseline, week 1, and week 8. One patient who did not start protocol therapy and one patient who
did not have metastatic breast cancer were excluded from all [18F]FDG-PET/CT analyses.
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Table A4. Cross-Tabulation of Week-1 v Week-8 Metabolic Response
Week-1 PET Response
Week-8 PET Response
PMR SMD PMD Unknown Total
Cohort 1
PMR 24 1 1 2 28
SMD 3 1 3 2 9
PMD 0 1 0 1 2
Unknown 0 0 0 1 1
Total 27 3 4 6 40
Cohort 2
PMR 16 5 0 0 21
SMD 2 16 2 2 22
PMD 0 0 0 0 0
Unknown 0 1 0 1 2
Total 18 22 2 3 45
NOTE. Seventy-five patients (cohort 1, 34; cohort 2, 41) were evaluable for comparison of week-1 v week-8 metabolic response by [18F]fluorodeoxyglucose positron
emission tomography/computed tomography according to European Organisation for Research and Treatment of Cancer criteria.
Abbreviations: PET, positron emission tomography; PMD, progressive metabolic disease; PMR, partial metabolic response; SMD, stable metabolic disease.






Yes No PPV (%) NPV (%)
Cohort 1
PMR 21 (75.0) 7 (25.0) 28 75 82
SMD/PMD 2 (18.2) 9 (81.8) 11
Unknown 0 (0.0) 1 (100.0) 1
Total 23 (57.5) 17 (42.5) 40
Cohort 2
PMR 12 (57.1) 9 (42.9) 21 57 77
SMD 5 (22.7) 17 (77.3) 22
Unknown 1 (50.0) 1 (50.0) 2
Total 18 (40.0) 27 (60.0) 45
NOTE. Patients were tabulated by clinical benefit (clinical benefit v no clinical benefit) and metabolic response (partial metabolic response [PMR] v stable metabolic
disease [SMD]/progressive metabolic disease [PMD]). Clinical benefit was defined as confirmed complete response plus confirmed partial response plus stable
disease  24 weeks. Patients with unconfirmed complete response, unconfirmed partial response, stable disease  24 weeks, and progressive disease as best
response were considered nonresponders for this analysis. Metabolic response was based on European Organisation for Research and Treatment of Cancer criteria.
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
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Table A6. Association Between Week-8 Metabolic Response and Objective Response by RECIST v1.0
Week-8 Metabolic Response Total
Objective Response
No. (%) Predictive Values
Responder Nonresponder PPV (%) 95% CI NPV (%) 95% CI
Cohort 1
PMR 27 19 (70) 8 (30) 70 53 to 88 100 100 to 100
SMD/PMD 7 0 (0) 7 (100)
Unknown 6 1 (17) 5 (83)
Total 40 20 (50) 20 (50)
Cohort 2
PMR 18 7 (39) 11 (61) 39 16 to 61 88 74 to 100
SMD 24 3 (13) 21 (88)
Unknown 3 0 (0) 3 (100)
Total 45 10 (22) 35 (78)
NOTE. Patients were tabulated by objective response (responder v nonresponder) and metabolic response (partial metabolic response [PMR] v stable metabolic
disease [SMD]/progressive metabolic disease [PMD]). Objective response was based on RECIST v1.0 (responder: confirmed complete response or partial response;
nonresponder: unconfirmed partial response, stable disease, progressive disease, or unknown). Metabolic response was based on European Organisation for
Research and Treatment of Cancer criteria.






































































































Fig A1. Waterfall plots of change in maximum standardized uptake value (SUVmax) relative to baseline. Dashed lines denote European Organisation for Research
and Treatment of Cancer cutoffs for metabolic response (25%) and progression (25%). Asterisks denote patients who were considered metabolic progressors on
the basis of new lesion(s). (A) Cohort 1 and (B) cohort 2 SUVmax at week 1 v baseline; (C) cohort 1 and (D) cohort 2 SUVmax at week 8 v baseline. PMD, progressive
metabolic disease; SMD, stable metabolic disease; PMR, partial metabolic response.
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Fig A2. Relationship between percentage change in maximum standardized uptake value (SUVmax) at week 1 and best percentage change of target lesions. Each
individual patient is plotted according to percentage change in SUVmax by [
18F]fluorodeoxyglucose positron emission tomography/computed tomography (CT)
comparing baseline and week 1 on the y-axis and according to best percentage change in sum of longest dimensions of target lesions relative to baseline by CT imaging
on the x-axis. Seven patients were considered RECIST nonresponders despite reductions of more than 30% in the sum of target lesions. Of these patients, six had
an initial partial response that was not confirmed on subsequent imaging 8 weeks later: one had stable disease  24 weeks and one had stable disease on initial
restaging and more than 30% on second restaging but in the setting of a new lesion and was therefore deemed a nonresponder.
Lin et al
© 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
